13 results
8-K
EX-99
GSTC
GlobeStar Therapeutics Corp
13 Nov 23
Other Events
12:32pm
;
Whereas Multiple Sclerosis (“MS”) is a chronic disease in which the immune system of the individual attacks the central nervous system and affects nerve
8-K
EX-99
GSTC
GlobeStar Therapeutics Corp
22 Jun 23
Globestar Therapeutics Enters into Mou with Advanced Innovative Partners to Develop Clinical Studies for Multiple Sclerosis Treatment
5:18pm
of chronic neurodegenerative diseases. In an initial study of Project Amethyst™ in Italy of 150 volunteers, 90 between 25 and 65 years of age with MS
8-K
EX-99
GSTC
GlobeStar Therapeutics Corp
12 Oct 21
Regulation FD Disclosure
8:27am
solutions to the medical community. With a focus on Multiple Sclerosis and other chronic diseases, GlobeStar’s team is committed to helping those
8-K
EX-99
GSTC
GlobeStar Therapeutics Corp
4 Oct 21
Regulation FD Disclosure
8:48am
on Multiple Sclerosis and other chronic diseases, GlobeStar’s team is committed to helping those suffering begin their journey back to health. More
8-K
GSTC
GlobeStar Therapeutics Corp
25 Feb 21
Angiosoma and its Subsidiary Somaceuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent
5:30pm
.
Multiple Sclerosis (MS) is a chronic disease in which the immune system of the individual attacks the central nervous system and affects the nerve
8-K
ayg4kc0 uo2y
9 Dec 20
SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis
12:00am
8-K
EX-99
ag04cpvr8wyyz0ugt
9 Dec 20
SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis
12:00am
8-K
n1t wh0dwzlnt
24 Aug 20
SomaCeuticals Acquires License for Treatment of Multiple Sclerosis
5:01pm
8-K
EX-99
qdqvjmllqhdhl
24 Aug 20
SomaCeuticals Acquires License for Treatment of Multiple Sclerosis
5:01pm
- Prev
- 1
- Next